Delving into the Latest Updates on Hainan Quanxing Pharmaceutical Co. Ltd. with Synapse

Overview

Tags

Other Diseases

Nervous System Diseases

Skin and Musculoskeletal Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	1
Infectious Diseases	1
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Small molecule drug	3

Top 5 Target	Count

CYP3A4(Cytochrome P450 3A4)	1

主要研究目的：考察空腹单次外用受试制剂双氯芬酸二乙胺乳胶剂（规格：1%[20g: 0.2g]，海南全星制药有限公司生产，北京阳光诺和药物研究股份有限公司提供）与参比制剂双氯芬酸二乙胺乳胶剂（商品名：扶他林®，规格：1%[20g: 0.2g]，GSK Consumer Healthcare Schweiz AG持证，GSK Consumer Healthcare SARL生产，北京阳光诺和药物研究股份有限公司提供在中国成年健康受试者体内的药代动力学特征，评价空腹状态下外用两种制剂的生物等效性。次要研究目的：评价空腹单次外用受试制剂和参比制剂在中国成年健康受试者中的安全性。

[Translation]

Main study objectives: To investigate the pharmacokinetic characteristics of the single-dose topical test preparation diclofenac diethylamine emulsion (specification: 1% [20g: 0.2g], produced by Hainan Quanxing Pharmaceutical Co., Ltd., provided by Beijing Sunshine Novo Pharmaceutical Research Co., Ltd.) and the reference preparation diclofenac diethylamine emulsion (trade name: Voltaren®, specification: 1% [20g: 0.2g], licensed by GSK Consumer Healthcare Schweiz AG, produced by GSK Consumer Healthcare SARL, provided by Beijing Sunshine Novo Pharmaceutical Research Co., Ltd.) in healthy adult Chinese subjects, and to evaluate the bioequivalence of the two topical preparations in the fasting state. Secondary study objectives: To evaluate the safety of the single-dose topical test preparation and the reference preparation in healthy adult Chinese subjects.

Start Date15 Jun 2025

Sponsor / Collaborator

Hainan Quanxing Pharmaceutical Co. Ltd.

CTR20243428

/ CompletedNot Applicable

中国健康受试者空腹状态下单次口服阿仑膦酸钠片的单中心、开放、随机、两制剂、两序列、四周期、完全重复交叉人体生物等效性预试验

[Translation] A single-center, open-label, randomized, two-formulation, two-sequence, four-period, fully repeated crossover bioequivalence pilot study of alendronate sodium tablets in Chinese healthy subjects in the fasting state

研究健康受试者空腹单次口服受试制剂阿仑膦酸钠片（海南全星制药有限公司，规格：70mg）与参比制剂阿仑膦酸钠片（商品名：福善美 ®，N.V. Organon，规格：70mg）在吸收程度和速度方面是否存在差异，评价受试制剂和参比制剂在空腹状态下给药时的生物等效性，观察受试制剂和参比制剂在健康受试者中的安全性。

[Translation]

To investigate whether there are differences in the extent and rate of absorption between the test preparation alendronate sodium tablets (Hainan Quanxing Pharmaceutical Co., Ltd., specification: 70 mg) and the reference preparation alendronate sodium tablets (trade name: Fosamax ®, N.V. Organon, specification: 70 mg) taken orally on an empty stomach in healthy subjects, to evaluate the bioequivalence of the test preparation and the reference preparation when administered on an empty stomach, and to observe the safety of the test preparation and the reference preparation in healthy subjects.

Start Date29 Sep 2024

Sponsor / Collaborator

Hainan Quanxing Pharmaceutical Co. Ltd.

CTR20242988

/ CompletedNot Applicable

中国健康受试者空腹及餐后状态下单次口服吡拉西坦片的单中心、开放、随机、两制剂、两序列、两周期、双交叉人体生物等效性试验

[Translation] A single-center, open-label, randomized, two-formulation, two-sequence, two-period, double-crossover bioequivalence study of a single oral dose of piracetam tablets in Chinese healthy volunteers under fasting and fed conditions

研究健康受试者空腹和餐后单次口服受试制剂吡拉西坦片（海南全星制药有限公司，规格：0.4 g）与参比制剂吡拉西坦片（商品名：Nootropil®；UCB Pharma S.A.，规格：0.8 g）在吸收程度和速度方面是否存在差异，评价受试制剂和参比制剂在空腹及餐后条件下给药时的生物等效性，观察受试制剂和参比制剂在健康受试者中的安全性。

[Translation]

To investigate whether there are differences in the extent and rate of absorption of the test preparation piracetam tablets (Hainan Quanxing Pharmaceutical Co., Ltd., specification: 0.4 g) and the reference preparation piracetam tablets (trade name: Nootropil®; UCB Pharma S.A., specification: 0.8 g) after a single oral administration on an empty stomach or after a meal in healthy subjects, to evaluate the bioequivalence of the test preparation and the reference preparation when administered on an empty stomach or after a meal, and to observe the safety of the test preparation and the reference preparation in healthy subjects.

Start Date01 Sep 2024

Sponsor / Collaborator

Hainan Quanxing Pharmaceutical Co. Ltd.

100 Clinical Results associated with Hainan Quanxing Pharmaceutical Co. Ltd.

Login to view more data

0 Patents (Medical) associated with Hainan Quanxing Pharmaceutical Co. Ltd.

Login to view more data

100 Deals associated with Hainan Quanxing Pharmaceutical Co. Ltd.

Login to view more data

100 Translational Medicine associated with Hainan Quanxing Pharmaceutical Co. Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 02 Sep 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Approved

3

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Propacetamol Hydrochloride	Pain More	Approved
Piperaquine Phosphate ( CYP3A4 )	Malaria More	Approved
Alendronate Sodium	Osteoporosis, Postmenopausal More	Approved